The Patent Finder

Terms ending in 2044

AstraZeneca AB

Every in-force patent on AstraZeneca AB's record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,178,876Conjugates Comprising Cleavable Linkers
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,337,038Conjugates Comprising Cleavable Beta-Glucuronide-Containing Linkers
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,758,555Pharmaceutical Formulations
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,686,707ANTI-STEAP2 Chimeric Antigen Receptors and Uses Thereof
In force
 · High confidence
Medlmmune, LLCIn forceHigh confidence
US 12,698,282Inhibitors of Myeloperoxidase
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,747,223N-(2-(3-Cyano-2-Azabicyclo[31.0]HEXAN-2-YL)-2-Oxoethyl)QUINOLINE-4-Carboxamides
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
US 12,653,828Polq Inhibitors
In force
 · High confidence
AstraZeneca ABIn forceHigh confidence
7 of 7 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited